Impacto Públicocivic observatory
Portuguêspt-PTEnglishcurrent languageEspañoles-ES

PUBLIC CONTRACT · 2024

Medicamento Carfilzomib ; Lenvatinib ; Vedolizumab

Contract value
€109,365.49
Signed on
16 December 2024
Procedure
Ao abrigo de acordo-quadro (art.º 259.º)

This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.

Record 11096335

PUBLISHED SUBJECT

41/5071/2024 - Medicamento Carfilzomib ; Lenvatinib ; Vedolizumab

Parties involved

Place of performance
Portugal, Faro, Faro
NUTS region
PT150 - Algarve

WHO BID

Awardee and competitors

Companies that IMPIC lists as the awardee and as competitors in this procedure.

Awardee
EISAI FARMACÊUTICA, Unipessoal Lda. · Tax ID 507847660
Awardee
AMGEN BIOFARMACÊUTICA, LDA. · Tax ID 502942959
Awardee
TAKEDA-FARMACEUTICOS PORTUGAL, LDA · Tax ID 502801204

Values and timeline

Contract price
€109,365.49
Procedure base price
€0.00
Total effective price
Not reported on Portal BASE
Publication date
19 December 2024
Award date
16 December 2024
Signing date
16 December 2024
Performance period
20 days

The contract price is the value agreed in the contract, not the amount paid.

Procedure and framework

Contract type
Aquisição de bens móveis
Procedure type
Ao abrigo de acordo-quadro (art.º 259.º)
Award criterion
Monofator
CPV code
33600000-6 - Produtos farmacêuticos
Legal basis
Artigo 259.º do Código dos Contratos Públicos
Regime
Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
Framework agreement
491/2023 - Concurso público internacional para formação do acordo quadro de medicamentos do foro oncológico e imunomoduladores
Centralised procedure
No
Environmental criterion
No
Notice
Not stated
Procedure identifier
7346825

Compare with other contracts

Search the same body, supplier, place or type of service to understand the context of the published index.

← Back to contracts